<p>PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.</p>

PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.

Episode 3 - PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.

Medla works on behalf of some of the significant international societies and congresses to bring you a series of officially licensed events and programs in oncology. These include ASCO, ESMO and SABCS.
On top of live events and videos, these podcasts provide another opportunity to catch up with critical updates - when and wherever you choose to.
You can expect thorough and informed discussions between experts in their field, who will leave you with their perspectives on emerging options for you to offer your patients.
In the first series of podcasts, A/Prof Ben Tran and Prof Lisa Horvath discuss prostate cancer and their takeouts from ASCO 2023.

Medicine

Health & Fitness

Medla works on behalf of some of the significant international societies and congresses to bring you a series of officially licensed events and programs in oncology. These include ASCO, ESMO and SABCS. On top of live events and videos, these podcasts provide another opportunity to catch up with critical updates - when and wherever you choose to. You can expect thorough and informed discussions between experts in their field, who will leave you with their perspectives on emerging options for you to offer your patients. In the first series of podcasts, A/Prof Ben Tran and Prof Lisa Horvath discuss prostate cancer and their takeouts from ASCO 2023.

Share Episode 3 - PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.

Sign up to save your podcasts

Episode 3 - PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.

Episode 3 - PARP inhibitors with novel hormonal agents in metastatic, castration-resistant prostate cancer.